The Pharmaceutical Market: United Kindom

Date: January 31, 2013
Pages: 120
Price:
US$ 1,295.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P35EE5F9E05EN
Leaflet:

Download PDF Leaflet

The Pharmaceutical Market: United Kindom
OVERVIEW OF THE PHARMACEUTICAL MARKET IN UNITED KINGDOM

Drugmakers and governments will increasingly enter agreements that provide some form of risk- sharing or price protection for new drugs. Since most European governments, including the UK authorities, are focussing on cost containment in the healthcare sector, alternative pricing schemes for medicines allow for budget control, as well as providing patients with access to highly innovative treatments. Guidance drafted by the National Institute for Health and Clinical Excellence (NICE) has recommended the use of Bristol-Myers Squibb 's Yervoy (ipilimumab) and Roche's Zelboraf ( vemurafenib) for the treatment of advanced skin cancer. These are the first new drugs approved for routine use by the UK's National Health Service for the disease in more than a decade. While this is positive news for both drugmakers, NICE's stamp of approval came only after the manufacturers of both drugs agreed to offer discounts, overturning a prior rejection of the treatments by the watchdog.

Headline Expenditure Projections:

Pharmaceuticals: GBP23.81bn (US$38.33bn) in 2011 to GBP23.74bn (US$37.27bn) in 2012; -0.3% in local currency terms and -2.8% in US dollar terms. Forecast unchanged from Q4 12.

Healthcare: GBP144.79bn (US$232.99bn) in 2011 to GBP149.35bn (US$234.48bn) in 2012; +3.2% in local currency terms and +0.6% in US dollar terms. Forecast unchanged from Q4 12.

Medical Devices: GBP5.89bn (US$9.48nn) in 2011 to GBP5.93bn (US$9.30bn) in 2012; +0.6% in local currency terms and -1.9% in US dollar terms. Forecast unchanged from Q4 12.

Competitive Landscape

The Competitive Landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
SWOT ANALYSIS

    UK Pharmaceuticals And Healthcare Industry SWOT
    UK Political SWOT
    UK Economic SWOT
    UK Business Environment SWOT

PHARMACEUTICAL BUSINESS ENVIRONMENT RATINGS

    Table: Western Europe Pharmaceuticals Risk/Reward Ratings, Q113
    Rewards
    Risks

UK MARKET SUMMARY

REGULATORY REGIME

    Pharmaceutical Advertising
    Intellectual Property Issues
    Pricing Regime
    Generic Drug Prices
    Generic Substitution
    OTC Prices
    Reimbursement Regime
    Patient Access Scheme
    Table: Patient Access Schemes in Published Guidance, 2007-10
    Patient Involvement in NHS

INDUSTRY TRENDS AND DEVELOPMENTS

    Epidemiology
    Non-Communicable Disease
    Communicable Diseases
    Healthcare Sector
    Healthcare Reforms
    Healthcare Funding
    Healthcare IT
    Health Insurance
    Research & Development
    Biotechnology
    Clinical Trials
    Medical Devices

INDUSTRY FORECAST SCENARIO

    Pharmaceutical Market Forecast
    Table: Pharmaceutical Sales Indicators,2008-2016
    Healthcare Market Forecast
    Table: Healthcare Expenditure Indicators, 2008-2016
    Table: Healthcare Governmental Indicators, 2008-2016
    Table: Healthcare Private Indicators, 2008-2016
    Key Growth Factors – Macroeconomic
    Table: Macroeconomic Activity
    Prescription Drug Market Forecast
    Table: Prescriptions & Cost by Therapeutic Area in the UK, 2011
    Table: Written Prescriptions, 2007-2011 (mn)
    Table: Prescriptions by Value, 2007-11 (GBPmn)
    Table: Prescription Drug Sales Indicators, 2008-2016
    Patented Drug Market Forecast
    Table: Patented Drug Market Indicators, 2008-2016
    Generic Drug Market Forecast
    Table: Prescriptions Written and Dispensed Generically in England by Value, 1996-11 (GBPmn)
    Table: Generic Prescribing Rates by Therapeutic Area in England, 2006-11 (% by Volume)
    Table: Generic Dispensing Rates by Therapeutic Area in England, 2006-11 (% by Volume)
    Table: Generic Drug Sales Indicators, 2008-2016
    OTC Medicine Market Forecast
    Table: OTC Sales by Therapeutic Category at Retail Prices, 2008-11 (GBPmn)
    Table: OTC Medicine Sales Indicators, 2008-2016
    Table: Medicine Sales Breakdown, 2005-2010
    Pharmaceutical Trade Forecast
    Table: Exports and Imports Indicators, 2008-2016
    Medical Device Market Forecast
    Table: Medical Devices Sales Indicators 2008-2016
    Other Healthcare Data
    Key Risks To BMI Forecasts

COMPETITIVE LANDSCAPE

    Pharmaceutical Industry
    Table: Pharmaceutical Production, 1995-10 (Euros 000s)
    Table: Top 20 UK-Based Pharmaceutical Companies According To Market Capitalisation
    Table: Top 20 UK-Based Biotechnology Companies According To Market Capitalisation
    Pharmaceutical Trade Associations
    Table: Association of British Pharmaceutical Industry (ABPI) Full Members, 2011
    Table: Members of the British Generic Manufacturers Association, 2012
    Table: Full Members of the Proprietary Association of Great Britain (PAGB), 2011
    Company Developments
    Wholesale Sector
    Table: Members of British Association of Pharmaceutical Wholesalers (BAPW), 2011
    Retail Sector
    Table: UK Registered Retail Pharmacies, 2010

COMPANY PROFILES

    Leading Local Manufacturers
    GlaxoSmithKline
    AstraZeneca
    Leading Multinational Manufacturers
    Pfizer
    Novartis
    Sanofi
    Merck & Co

DEMOGRAPHIC OUTLOOK

    Table: The United Kingdom’s Population By Age Group, 1990-2020 (‘000)
    Table: The United Kingdom’s Population By Age Group, 1990-2020 (% of total)
    Table: The United Kingdom’s Key Population Ratios, 1990-2020
    Table: The United Kingdom’s Rural And Urban Population, 1990-2020

GLOSSARY

BMI METHODOLOGY

    How We Generate Our Pharmaceutical Industry Forecasts
    Risk/Reward Ratings Methodology
    Ratings Overview
    Table: Pharmaceutical Business Environment Indicators
    Weighting
    Table: Weighting Of Components
Skip to top


The Pharmaceutical Market: Chile US$ 1,295.00 Jan, 2013 · 141 pages
The Pharmaceutical Market: China US$ 1,295.00 Jan, 2013 · 118 pages
The Pharmaceutical Market: Colombia US$ 1,295.00 Jan, 2013 · 114 pages
The Pharmaceutical Market: Croatia US$ 1,295.00 Jan, 2013 · 86 pages
The Pharmaceutical Market: Cuba US$ 1,295.00 Mar, 2013

Ask Your Question

The Pharmaceutical Market: United Kindom
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: